2020年4月15日
Antegrade Balloon Aortic Valvuloplasty for the Highly Frail Patient of Severe Aortic Stenosis Complicated with Transthyretin-type Cardiac Amyloidosis.
Internal medicine (Tokyo, Japan)
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 59
- 号
- 8
- 開始ページ
- 1053
- 終了ページ
- 1057
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.2169/internalmedicine.3870-19
Transcatheter aortic valve implantation (TAVI) is widely accepted as the treatment for patient with severe aortic stenosis (AS) whose prognosis may be over one year; however, there is no consensus concerning extremely high-risk patients whose prognosis may not exceed one year. We herein report a highly frail patient with severe AS complicated with transthyretin-type cardiac amyloidosis who had a very poor prognosis. Given his condition, we treated him by percutaneous antegrade balloon aortic valvuloplasty (A-BAV) instead of TAVI. A-BAV may be a beneficial option for treating extremely high-risk severe AS patients, including those with cardiac amyloidosis.
- リンク情報
- ID情報
-
- DOI : 10.2169/internalmedicine.3870-19
- PubMed ID : 31875637
- PubMed Central 記事ID : PMC7205528